Patents by Inventor Christopher Chapron

Christopher Chapron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TGFB INHIBITORS AND USE THEREOF
    Publication number: 20230057012
    Abstract: Disclosed herein are novel inhibitors of TGF?1 activation with durable inhibitory effects. Methods directed to the selection of a suitable TGF? inhibitor for various disease conditions and patient populations are also provided.
    Type: Application
    Filed: January 11, 2021
    Publication date: February 23, 2023
    Inventors: Stefan Wawersik, Thomas Schurpf, Christopher Chapron, Sandeep Kumar, Adam Fogel
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20220064275
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: August 19, 2021
    Publication date: March 3, 2022
    Inventors: Abhishek DATTA, Allan CAPILI, Thomas SCHURPF, Constance MARTIN, Kevin B. DAGBAY, Christopher CHAPRON, Stefan WAWERSIK, Christopher LITTLEFIELD, Gregory J. CARVEN, Alan BUCKLER, Susan LIN, Justin W. JACKSON, Caitlin STEIN, Matthew SALOTTO, Andrew AVERY, Anthony COOPER
  • TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210340238
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: November 4, 2021
    Inventors: Abhishek Datta, Thomas Schurpf, Allan Capili, Stefan Wawersik, Christopher Chapron, Christopher Littlefield, Gregory J. Carven, Kevin B. Dagbay, Susan Lin, Justin W. Jackson, Caitlin Stein
  • Isoform-selective TGF?1 inhibitors and use thereof
    Patent number: 11130803
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: September 28, 2021
    Assignee: Scholar Rock, Inc.
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Matthew Salotto, Andrew Avery, Anthony Cooper
  • HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF
    Publication number: 20210122814
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: April 29, 2021
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson, Caitlin Stein, Andrew Avery, Anthony Cooper, Matthew Salotto
  • ISOFORM-SELECTIVE TGFB1 INHIBITORS AND USE THEREOF
    Publication number: 20200079840
    Abstract: Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF?1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
    Type: Application
    Filed: July 11, 2019
    Publication date: March 12, 2020
    Inventors: Abhishek Datta, Allan Capili, Thomas Schurpf, Constance Martin, Kevin B. Dagbay, Christopher Chapron, Stefan Wawersik, Christopher Littlefield, Gregory J. Carven, Alan Buckler, Susan Lin, Justin W. Jackson